EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge
Patient group input requested for a new Joint Assessment on a medicinal product for cerebral adrenoleukodystrophy (CALD).
This is the second pharmaceutical Rapid Collaborative Review (PTRCR18) published by EUnetHTA. This report describes dexamethasone for the treatment of COVID-19 patients. In September, 2020,
The Final Report on Implementation, a deliverable of EUnetHTA Joint Action 3 (2016-2021), explores the use of joint assessments (JA) and collaborative assessments (CA) during
PTJA08 – Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity
This is the pharmaceutical Joint Assessment PTJA08 – on siponimod for the treatment of active SPMS. In January 2020, the European Commission granted marketing authorisation
PTJA06 – Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
This is the pharmaceutical Joint Assessment PTJA06 – on polatuzumab vedotin for the treatment of relapsed/refractory DLBCL. In January 2020, The European Commission granted conditional
The final assessment report and related documents for the Other Technologies Collaborative Assessment ‘Point-of-care Tests (POCT): D-Dimer and Troponin’ are now available for access. Troponin
EUnetHTA is pleased to announce the new Implementation Report with Appendices are now available for access. The report covers the updated use and uptake on
PTJA06 – “Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL)” final project plan now available.
The final project plan of the assessment on polatuzumab is now available. The final assessment report will be published on 13th February, 2020. Please access
The final assessment report and related documents for the Other Technologies Collaborative Assessment ‘Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in